To substantiate cross-protection reported across AS04-adjuvanted bivalent human papillomavirus (HPV) vaccine (2vHPV) studies, we reevaluated vaccine effectiveness against type-specific HPV positivity as a function of phylogenetic distance to vaccine target types HPV-16 and-18. We provide evidence of sustained cross-protection up to 8 years postvaccination in a high-risk population in the Netherlands. Moreover, our findings suggest that genomic distance better explains cross-protection than distance measures based on capsid antigens only. Taken together, 2vHPV is predicted to provide partial cross-protection against HPV-31,-33,-35,-45,-52, and possibly-58, that is, acknowledged oncogenic types with close phylogenetic relationships to HPV-16 or-18.
Bogaards, J. A., van der Weele, P., Woestenberg, P. J., van Benthem, B. H. B., & King, A. J. (2019). Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates with Phylogenetic Distance from HPV Vaccine Types 16 and 18. Journal of Infectious Diseases, 220(7), 1141-1146. https://doi.org/10.1093/infdis/jiz280